The apparent uncoupling of the dynamics of the peripheral TCR repertoire with tumor response therefore questions the role of the T cell reinvigoration induced by CTLA-4 blockade in the periphery in leveraging the anti-tumoral action of the treatment. The gene discussed is CTLA4; the disease is neoplasm.